Sphere Fluidics Launches Cyto-Mine Chroma and Announces Early Access Program
Sphere Fluidics, a leading provider of innovative picodroplet-based microfluidics solutions for functional single cell analysis and isolation, today announced the launch of Cyto-Mine ® Chroma and the opening of its Early Access Program at SLAS2025 International Conference and Exhibition in San Diego.
Cyto-Mine Chroma represents the next generation of Sphere Fluidics' industry-leading Cyto-Mine single-cell analysis platform. The Early Access Program provides an opportunity to be among the first to demo the Cyto-Mine Chroma for faster project timeline completion and improved outcomes across broad applications, including antibody discovery, cell line development, and emerging areas such as cell therapy. Through the program, the Company will collaborate closely with forward-thinking customers to drive innovation and inform the development of future applications and assays on the platform.
Offering enhanced capabilities, including multiplexing and greater assay flexibility, Cyto-Mine Chroma has been developed to maximize the efficiency and precision of single-cell functional analysis – enabling tens of millions of cells to be screened in a day. Leveraging a four-color laser and detector system, Cyto-Mine Chroma expands the number of parameters that can be analyzed for each cell in a single assay. This supports the upcoming launch of the Company's first multiplexed assay kit, facilitating multiple readouts within a single experiment, optimizing the throughput and precision of cell selection. By accelerating the early selection of superior candidate cells for downstream expansion or further analysis, overall timelines are reduced from months to weeks, while reducing effort and cost.
Sphere Fluidics will be showcasing Cyto-Mine Chroma at its booth (#2744) at SLAS2025. Chief Technology Officer, Richard Hammond, will be presenting a Solutions Spotlight demonstrating the new platform's capabilities on day two of the conference, Tuesday January 28 th, 12:00 – 12:20pm.
'The next-generation Cyto-Mine Chroma platform has been designed to transform single-cell analysis. We are excited to unveil this innovative platform and its Early Access Program at SLAS, the premier event for lab automation and screening. This launch underscores our dedication to advancing biotechnology. Collaborating closely with key industry stakeholders and researchers will allow us to ensure our microfluidic technologies meet the evolving needs of the sector, both now and in the future.' commented Dale Levitzke, CEO, Sphere Fluidics.
CONTACT: For further information please contact:
Dr Claire Cox
Sphere Fluidics Ltd.
Tel: +44 (0)7365 209 441
Zyme Communications
Lily Jeffery
KEYWORD: UNITED KINGDOM EUROPE
SOURCE: Sphere Fluidics
Copyright Business Wire 2025.
PUB: 01/27/2025 04:22 AM/DISC: 01/27/2025 04:22 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
16 minutes ago
- Business Wire
Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. ('Agenus' or the 'Company') (Nasdaq: AGEN), an immuno-oncology company focused on innovation, today reports financial results for the second quarter of 2025 and highlighted major clinical, regulatory, and operational milestones supporting the advancement of its botensilimab (BOT) and balstilimab (BAL) immunotherapy combination. Botensilimab is a next-generation, multifunctional, Fc enhanced, CTLA-4 antibody and BAL is a proprietary PD-1 antibody; together they are designed to trigger robust and durable immune attacks against 'cold,' treatment-resistant tumors, offering new hope where standard therapies have failed. 'Our team is committed to advancing BOT/BAL to deliver meaningful benefits to patients with treatment-resistant cancers, and we are working with regulatory agencies to expedite access through a streamlined Phase 3 trial,' said Garo Armen, Ph.D., Chairman and Chief Executive Officer of Agenus. 'With significant clinical progress, strategic partnerships, and prudent financial management, we are well-positioned to execute our vision of transforming cancer care.' Regulatory Highlights Breakthrough Survival in Refractory MSS CRC – At the 2025 ESMO Gastrointestinal Cancers Congress, BOT + BAL reported a 42% two-year survival rate and median overall survival of ~21 months in a trial of 123 patients with refractory no liver met MSS metastatic colorectal cancer (mCRC). Regulatory Alignment on Registrational Phase 3 Trial (BATTMAN) – Following an End-of-Phase 2 meeting on July 1, 2025, the FDA agreed to a streamlined two-arm BATTMAN Phase 3 design, having agreed to BOT/BAL's contribution of components. This agreement also marks a shift from a three-arm trial previously proposed by regulators and enables trial initiation in Q4 2025. Expanding Evidence Across Tumor Types – New data from a neoadjuvant pan-cancer trial (NEOASIS study) showed robust pathological responses across MSS and MSI-H solid tumors, including triple-negative breast cancer, with no dose-limiting toxicities. Translational data from ASCO confirmed BOT/BAL's ability to activate T cells and address resistance in MSS tumors, supporting its potential across cancers. 'The BOT/BAL combination is delivering durable responses and survival outcomes in refractory MSS colorectal cancer,' said Richard M. Goldberg, M.D., Chief Development Officer of Agenus. 'With regulatory clarity and a focused development team, we are poised to execute the BATTMAN trial and explore earlier treatment settings to maximize patient impact.' Strategic Partnerships Zydus Lifesciences Collaboration – The collaboration for U.S. manufacturing and commercialization in India/Sri Lanka is progressing toward a Q3 2025 closing, delivering $91M in upfront capital and equity investment upon closing to support development and regulatory activities. Noetik AI Biomarker Collaboration using AI algorithms – Agenus commenced a partnership with Noetik AI to refine patient selection, enhancing BOT/BAL's clinical impact and unlocking potential future revenue streams through precision oncology. Broader Portfolio Synergies – Agenus continues to leverage its significant ownership of MiNK Therapeutics and SaponiQx, to advance combination treatments with adoptive cell therapies and adjuvants, broadening its immuno-oncology pipeline. Key 2H 2025 Catalysts— Building on recent clinical, regulatory, and partnership momentum, Agenus anticipates several significant milestones in the second half of 2025: Registrational Trial Launch – In Q4 2025, initiate the global BATTMAN Phase 3 trial of BOT/BAL in refractory MSS CRC in partnership with the Canadian Clinical Trials Group (CCTG), committed to executing with speed and precision. Significant Clinical Data Generation – Expand evidence for BOT/BAL's activity in earlier-line and neoadjuvant MSS colorectal cancer and other tumors through strategic collaborations and investigator-sponsored trials. Upcoming Data Presentations – Share new BOT/BAL clinical results in colorectal and other solid tumors at major oncology congresses in Q4 2025, reinforcing its therapeutic potential. Financial Highlights— Agenus continues to strengthen its financial position through prudent cost management and strategic capital-raising efforts in addition to Zydus collaboration, positioning the company to execute its clinical and regulatory objectives. Key financial metrics for Q2 2025 are summarized below: Revenue and Net Loss – Agenus reported revenue of $25.7 million for Q2 2025 and $49.8 million for Q2 YTD 2025, primarily from non-cash royalty revenue, compared to $51.5 million in Q2 YTD 2024. The net loss Q2 YTD 2025 was $56.4 million, or $2.03 per share, a significant improvement from $118.3 million, or $5.56 per share, for Q2 YTD 2024. Reduced Cash Burn – Cash used in operations decreased to $45.8 million for Q2 YTD 2025 from $76.4 million for Q2 YTD 2024. These reductions are a consequence of prudent cost management and are expected to continue into the second half of 2025. Agenus is also in active negotiations for collaborations that could result in additional significant infusions of cash resources. Liquidity and Future Outlook – With the $91 million Zydus infusion expected upon closing, combined with its current cash balance, Agenus expects to fund the launch of its Phase 3 trial. Further, the company is in negotiations to secure additional funding streams from partnerships currently under negotiation and BOT/BAL's commercial prospects in geographies beyond North America, Europe and Japan. Webcast and Conference Call Information The Company will host a webcast and Stakeholder Briefing on August 27, 2025, to review Q2 financial results, anticipated data milestones, and the global BOT/BAL development program. About Agenus Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. Founded in 1994, Agenus is advancing antibody therapeutics, adoptive cell therapies through MiNK Therapeutics, and adjuvants through SaponiQx, leveraging robust end-to-end development capabilities, including commercial and clinical cGMP manufacturing facilities and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit or @agenus_bio. Agenus' Commitment to Patient Access Agenus is dedicated to making investigational medicines available to patients with cancer at the appropriate time and in the correct manner. For more information, visit About Botensilimab (BOT) Botensilimab (AGEN1181) is a next-generation, multifunctional, Fc-enhanced CTLA-4 antibody engineered to boost both innate and adaptive anti-tumor immune responses. Its unique design aims to overcome the limitations of first-generation CTLA-4 inhibitors (like ipilimumab) and extend immunotherapy benefits to 'cold' tumors that typically respond poorly or not at all to standard immune checkpoint blockade. Botensilimab's Fc-enhanced structure allows it to robustly engage activating Fc receptors on key immune cells, thereby priming and activating T cells, depleting immunosuppressive regulatory T cells in the tumor microenvironment, activating myeloid cells, and inducing long-term immune memory. Through these mechanisms, botensilimab has demonstrated the ability to ignite immune responses across a range of solid tumors, including those resistant to conventional PD-1 or CTLA-4 therapies. To date, approximately 1,200 patients have been treated with botensilimab and/or balstilimab in Phase 1 and 2 trials. Botensilimab alone or in combination with Agenus' investigational PD-1 antibody balstilimab has shown clinical responses in nine different metastatic cancers in late-line settings. For more information on ongoing botensilimab trials, please visit About Balstilimab (BAL) Balstilimab (AGEN2034) is a novel, fully human monoclonal IgG4 antibody that blocks PD-1 (programmed cell death-1) from interacting with its ligands PD-L1 and PD-L2. By inhibiting the PD-1 checkpoint pathway, balstilimab aims to restore T-cell activity against tumors. It has been evaluated in over 900 patients to date and has demonstrated clinical activity with a favorable tolerability profile in several tumor types. Balstilimab is being studied both as a monotherapy and in combination with other agents (such as botensilimab) to expand its therapeutic impact. Forward-Looking Statements This press release contains forward-looking statements made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the botensilimab and balstilimab clinical programs, expected trial initiations, regulatory plans, and potential benefits of the combination therapy. These statements are subject to risks and uncertainties described in Agenus' most recent Annual Report on Form 10-K for 2024 and subsequent Quarterly Reports on Form 10-Q filed with the SEC. Agenus cautions investors not to place undue reliance on these statements, which speak only as of the date of this announcement. The company undertakes no obligation to update or revise these statements, except as required by law.
Business Wire
16 minutes ago
- Business Wire
Real Luxury Tapped to Lead Sales and Marketing for Bozeman Yards—Bozeman's Boldest New Luxury Condo Development
MIAMI--(BUSINESS WIRE)--The Real Brokerage Inc. (NASDAQ: REAX), a leading real estate technology platform redefining the industry through innovation and culture, today announced that Real Luxury, the company's elite division focused on high-end real estate, has been selected to lead sales and marketing for Bozeman Yards, a landmark new luxury condominium development in Bozeman, Mont. Expected to surpass $100 million in total sales, Bozeman Yards is poised to set a new standard for amenities and quality of life in Bozeman's growing luxury real estate market. 'This project perfectly blends urban luxury living, nature, design and lifestyle. It's an embodiment of modern luxury in one of the most dynamic emerging markets in the West,' said Kofi Nartey, Executive Director of Real Luxury. Leading the effort are Kofi Nartey, Executive Director of Real Luxury, and Amelia Turbyfill, Real Luxury Regional Director for the Northwest. In collaboration with Bozeman Realty Group, Nartey and Turbyfill will oversee the full sales strategy and marketing campaign, bringing together national prestige, global reach and deep local market expertise to attract a new wave of luxury buyers. 'We are thrilled to bring Bozeman Yards to market,' Nartey said. 'This project perfectly blends urban luxury living, nature, design and lifestyle. It's an embodiment of modern luxury in one of the most dynamic emerging markets in the West.' Redefining Mountain Luxury Living Phase One of Bozeman Yards will include 39 thoughtfully designed residences, featuring premium penthouses, a state-of-the-art wellness center, full gym, plunge pool and stunning views of the Bridger Mountains. The project offers a unique lifestyle proposition for affluent buyers who desire high-design, access to nature and community without the density or saturation of traditional luxury hubs. With the private Yellowstone Club nearby and the highly anticipated One & Only Moonlight Basin coming to Big Sky, Bozeman is quickly becoming a preferred alternative to conventional high-end resort towns, offering exclusivity, authenticity and lifestyle. 'Today's buyers want experience, privacy, nature and a strong sense of place,' Turbyfill said. 'Bozeman Yards is more than a development. It's a destination for those seeking to live well, breathe deep and invest in a lifestyle as much as a property. It embodies everything Bozeman stands for and everything discerning buyers are looking for.' Strong Early Interest With full delivery projected for Fall 2027, Bozeman Yards is already drawing strong demand, with over 25% of residences reserved during the pre-launch phase. Interest spans regional second-home buyers to national investors seeking long-term lifestyle and equity upside in Montana's fastest-growing market. To learn more or schedule a private appointment, please email Turbyfill at a@ or Nartey at kofi@ About Real Real (NASDAQ: REAX) is a real estate experience company working to make life's most complex transaction simpler. The fast-growing company combines essential real estate, mortgage and closing services with powerful technology to deliver a single seamless end-to-end consumer experience, guided by trusted agents. With a presence in all 50 states throughout the U.S. and Canada, Real supports over 29,000 agents who use its digital brokerage platform and tight-knit professional community to power their own forward-thinking businesses. Additional information can be found on its website at Forward-Looking Statements Some of the statements in this press release are "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995, including statements regarding agent growth. These forward-looking statements are subject to risks, uncertainties and assumptions, including the risk of slowdowns in real estate markets, economic and industry downturns and Real's ability to attract new agents and retain current agents. Accordingly, these forward-looking statements should be evaluated with consideration given to the many risks and uncertainties that could cause actual results and events to differ materially from those in the forward-looking statements. They include the risks discussed under the heading 'Risk Factors' in the Company's Annual Information Form dated March 6, 2025, and 'Risks and Uncertainties' in the Company's Quarterly Management's Discussion and Analysis for the period ended June 30, 2025, copies of which are available under the Company's SEDAR+ profile at It is not possible for management to predict all the possible risks that could affect Real or to assess the impact of all possible risks on Real's business.
Business Wire
16 minutes ago
- Business Wire
Aramark Collegiate Hospitality Meets Student Tastes for Unique Campus Experiences
PHILADELPHIA--(BUSINESS WIRE)--As the 2025–2026 school year begins, Aramark Collegiate Hospitality is responding to today's campus needs by listening closely and taking thoughtful action to align with each university's unique culture. From tailored food options to updated meal plans, Aramark shows that campus dining is about more than just meals—it's about building connection, community, and belonging. 'Students are telling us what matters to them, and we're responding in real time,' said Jack Donovan, President and CEO for Aramark Collegiate Hospitality. 'It's not just about collecting data—it's about creating campus hospitality experiences that feel personal and purposeful and understanding students on a deeper level.' Aramark is reworking its entire suite of listening and survey tools to better capture the voice of the current student. These updates include retooled intuitive and student-friendly surveys that feature refined terminology and question design, as well as enhanced analytics and reporting capabilities. These improvements allow for sharper, more meaningful insights and faster, more effective responses to student needs. Culinary Innovation That Reflects Student Tastes Aramark is leading the way in culinary creativity with new concepts and partnerships that align with popular 'create-your-own" trends including: MEDI – A Mediterranean-inspired dining solution piloted in Spring 2025 and rolling out widely this fall, MEDI is affordable, flexible, and on-trend—earning high marks from students during pilot testing. Signature dishes include a Chicken Shawarma Grain Bowl, a Lamb Meatball Bowl, and a make-your-own option designed to satisfy individual preferences. Chef Grace Ramirez Partnership – In the fall 2025, Aramark's ongoing collaboration with Chef Grace Ramirez expands La Latina Cocina to bring Latin American flavors to campuses. Students will choose from signature and made-to-order plates, bowls, tacos, and more. One highlight is the El Choripán Platter—grilled chorizo with guasacaca, pickled cabbage, and cilantro crema on a roll, served with chili-lime chips. Campus Smokehouse – Campus Smokehouse is rooted in time-honored smoking techniques and bold ingredients. Guests will be offered slow-smoked BBQ staples like pulled pork, smoked chicken, saucy wings, and even smoky jackfruit for a plant-based option, and pair them with down-home sides including baked beans and country-style green beans. Dining Concepts That Foster Community Beyond the plate, Aramark is investing in spaces that foster belonging and support campus pride and affinity. The upcoming The Gathering Place ™, set to pilot in Spring 2026, is designed as a personalized campus space where students can celebrate traditions, build school spirit, and develop friendships. Restaurant DestiNATIONS continues to bring global cuisine to campus through rotating restaurant-style takeovers, offering both customizable and chef-curated options that enable students to explore the world through food. Rolling out throughout 2025-2026, REVIVE is a wellness-focused residential dining concept that nurtures mental, emotional, and physical health. With its 'Nourish to Flourish' philosophy, it offers a health-forward culinary program and a welcoming campus hub where everyone on campus can come to recharge, connect, and thrive through smart eating and community engagement. A Future Fueled by Insights Aramark has launched TrendScoop, a quarterly review of culinary, collegiate, and generational insights for both operators and campus partners. And this fall, the debut of StudentLounge ™—an online platform for asynchronous student feedback—will deepen the company's connection with its audience in ways that students are most comfortable providing feedback. Insights gleaned from Aramark's research show that students give the highest marks for flexibility, personalization, and convenience. To meet that need, Aramark has developed several solutions. Next Gen Meal Plans – 'Create Your Own' and 'Try Before You Buy' options put students in control, and a new graduate student meal program has been added to the suite of plans. These options give students the power to match personal preferences with meal plans that fit their lifestyles. Fingertip Tech Access – The next generation of campus dining web and app access will be rolling out via Collegiate Hospitality's new myDiningHub platform. Starting this fall, campuses will be upgrading their current websites, and the next phase will feature an app roll-out. Grab & Gather ™ – After a successful pilot program, Grab & Gather will be available for use at all Aramark Collegiate Hospitality accounts that offer mobile ordering for their retail locations. This small-scale catering solution bridges the gap between take-out and formal event catering in a way that is convenient and affordable for student campus groups' meetings and get-togethers. About Aramark Collegiate Hospitality Aramark Collegiate Hospitality is a premier provider for hospitality ecosystems in higher education, renowned for its commitment to the whole student and enhancing student life through exceptional culinary experiences and innovative dining solutions. With a presence in more than 275 colleges and universities, Collegiate Hospitality uses data driven consumer insights to curate experiences to meet the unique needs of each campus, fostering a vibrant community with diverse and inclusive dining offerings. This intentional integration of campus identity, world class hospitality, and professional opportunity provides a foundational path to student success. Connect with Collegiate Hospitality on LinkedIn. Aramark (NYSE: ARMK) proudly serves the world's leading educational institutions, Fortune 500 companies, world champion sports teams, prominent healthcare providers, iconic destinations and cultural attractions, and numerous municipalities in 16 countries around the world with food and facilities management. Because of our hospitality culture, our employees strive to do great things for each other, our partners, our communities, and the planet.
